Krystal Angeli Valdez
Endocrinology, Diabetes & Metabolism · San Luis Obispo, CANPI 1629480272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,715, 4.1 times the $906 reported in 2019.
Across 198 payments — averaging $41.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Abbott$709
- Tandem Diabetes Care, Inc.$707
- Dexcom, Inc.$679
- Insulet Corporation$596
- Lilly USA, LLC$505
- plus $3K from 18 others
What the payments were for
- Food & beverage$8,02698%
- Education$1081%
- Other$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 42 | $1,815 |
| Abbott | 8 | $709 |
| Tandem Diabetes Care, Inc. | 14 | $707 |
| Dexcom, Inc. | 18 | $679 |
| Insulet Corporation | 16 | $596 |
| Lilly USA, LLC | 15 | $505 |
| Xeris Pharmaceuticals, Inc. | 16 | $438 |
| Cequr Corporation | 2 | $387 |
| Bayer | 9 | $340 |
| Boehringer Ingelheim | 5 | $304 |
| Medtronic(2 entities) | 4 | $282 |
| Mannkind Corporation | 12 | $250 |
| Novo Nordisk | 10 | $206 |
| Companion Medical, Inc. | 2 | $195 |
| Sanofi-aventis U.S. LLC | 6 | $174 |
| Merck | 4 | $133 |
| Corcept Therapeutics | 5 | $99 |
| AstraZeneca | 1 | $84 |
| Neurocrine Biosciences, Inc. | 3 | $84 |
| Shire North American Group Inc | 1 | $74 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 1 | $26 |
| Radius Health, Inc. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$744
- CeQur Simplicity$387
- Omnipod$364
- FREESTYLE LIBRE 3$257
- EVENITY$246
- JARDIANCE$241
- Kerendia$234
- t:slim X2 Insulin Pump with Control-IQ$231
- GALLANT$148
- MINIMED 780G$130
- RECORLEV$129
- ZEPBOUND$124
- Prolia$123
- MOUNJARO$119
- STEGLATRO$115
How this compares
$8,174 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $223,602 |
| JardianceEmpagliflozin | 114 | $135,191 |
| TrulicityDulaglutide | 30 | $45,183 |
| RybelsusSemaglutide | 25 | $43,660 |
| MounjaroTirzepatide | 36 | $38,507 |
| FarxigaDapagliflozin Propanediol | 30 | $23,804 |
| JanuviaSitagliptin Phosphate | 11 | $15,678 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $14,418 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,603 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 90 | $11,218 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 17 | $8,886 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $7,624 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $7,069 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $4,266 |
| Novolog FlexpenInsulin Aspart | 11 | $2,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $206 | $267,262180 claims |
| Boehringer IngelheimJardiance | $304 | $135,191114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $505 | $83,69066 claims |
| MerckJanuvia, Janumet | $133 | $27,28124 claims |
| AstraZenecaFarxiga | $84 | $23,80430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Luis Obispo
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.